Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
09/2003
09/02/2003US6613801 Method for the synthesis of compounds of formula I and their uses thereof
09/02/2003US6613769 Tryptase inhibitors
09/02/2003US6613349 Bactericides
08/2003
08/28/2003WO2003070970A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA)
08/28/2003WO2003070968A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070965A2 The eaat2 promoter and uses thereof
08/28/2003WO2003070918A2 Rna interference by modified short interfering nucleic acid
08/28/2003WO2003070914A2 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070911A2 Rna interference mediated inhibition of type 1 insulin-like growth factor receptor (igf-1r)
08/28/2003WO2003070910A2 INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070903A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070886A2 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid
08/28/2003WO2003070765A2 Growth hormone fusion protein
08/28/2003WO2003070755A2 Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
08/28/2003WO2003070751A2 Partial peptide mimetics and methods
08/28/2003WO2003070744A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070738A2 Topiramate salts and compositions comprising and methods of making and using the same
08/28/2003WO2003070732A1 Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
08/28/2003WO2003070731A2 Azabicyclic compounds for the treatment of disease
08/28/2003WO2003070727A1 Thiazolyl urea compounds for the treatment of cancer
08/28/2003WO2003070711A1 Oxa- and thiadiazoles and their use as metalloproteinase inhibitors
08/28/2003WO2003070707A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
08/28/2003WO2003070706A1 Tricyclic pyrazole derivatives for the treatment of inflammation
08/28/2003WO2003070269A1 Treatment for diseases of the eye, inner ear and central nervous system
08/28/2003WO2003070256A1 Hyaluronic acid mediated adenoviral transduction
08/28/2003WO2003070249A1 Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis
08/28/2003WO2003070246A1 Controlled synthesis of ziprasidone and compositions thereof
08/28/2003WO2003070242A1 Piperidin-4-yl urea derivatives and related compounds as chemokine receptor inhibitors for the treatment of inflammatory diseases
08/28/2003WO2003070235A1 Medicinal compositions for inhibiting tryptase
08/28/2003WO2003070219A1 Drug delivery system for the subconjunctival administration of fine grains
08/28/2003WO2003070204A2 Lipase inhibiting composition
08/28/2003WO2003070197A2 RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070184A2 Sodium channel blockers
08/28/2003WO2003070182A2 Sodium channel blockers
08/28/2003WO2003043986A8 Polypeptides of moraxella (branhamella) catarrhalis
08/28/2003WO2003031447A3 Pyrimidine derivatives
08/28/2003WO2003027116A3 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
08/28/2003WO2003017990A3 Ophthalmic composition comprising an ascomycin
08/28/2003WO2003013434A3 Methods and compositions for treating diseases associated with excesses in ace
08/28/2003WO2002094192A3 Antibodies against tumor necrosis factor delta (april)
08/28/2003WO2002077021A3 Streptococcus pneumoniae proteins and nucleic acids
08/28/2003WO2002041880A3 Use of pyrazolo[4,3-d]pyrimidines
08/28/2003WO2002015885A3 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
08/28/2003US20030163834 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of Erk-5
08/28/2003US20030162969 Process and intermediates for pyridazinone antidiabetic agents
08/28/2003US20030162964 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
08/28/2003US20030162819 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
08/28/2003US20030162808 Acetindine derivatives, their preparation and medicaments containing them
08/28/2003US20030162798 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments
08/28/2003US20030162779 4-oxo-4H-thiazole derivative for treating or preventing neurodegenerative disorders
08/28/2003US20030162775 Heterocyclic substituted pyrazolones
08/28/2003US20030162767 Novel 1,3-dihydro-2h-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them
08/28/2003US20030162765 Use in treatment and prevention of central nervous system and other disorders
08/28/2003US20030162764 Pyrimidine A2b selective antagonist compounds, their synthesis and use
08/28/2003US20030162758 Using regulation of pathogenic mechanisms similar to atherosclerosis; utilizing regulation of reverse cholesterol transport
08/28/2003US20030162747 Administering otoprotectant glutathione peroxidase mimic (ebselen), xanthine oxidase inhibitor (allopurinol), and glutathione precursor (N-acetylcysteine)
08/28/2003US20030162736 Medicament comprising NK4 gene or recombinant NK4 protein
08/28/2003US20030162175 NK cell receptor polynucleotides, polypeptides, and antibodies
08/28/2003US20030161884 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
08/28/2003US20030161883 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis
08/28/2003US20030161826 Therapy for autoimmune disease; central nervous system disorders
08/28/2003US20030161816 Systems and methods for treating patients with processed lipoaspirate cells
08/28/2003CA2486381A1 Lipase inhibiting composition
08/28/2003CA2476935A1 Drug delivery system for subconjunctival administration of fine particles
08/28/2003CA2476837A1 Sodium channel blockers
08/28/2003CA2476681A1 Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
08/28/2003CA2476665A1 Tricyclic pyrazole derivatives for the treatment of inflammation
08/28/2003CA2476624A1 Azabicyclic compounds for the treatment of disease
08/28/2003CA2476451A1 Hyaluronic acid mediated adenoviral transduction
08/28/2003CA2476427A1 Partial peptide mimetics and methods
08/28/2003CA2476422A1 Topiramate salts and compositions comprising and methods of making and using the same
08/28/2003CA2476411A1 Thiazolyl urea compounds for the treatment of cancer
08/28/2003CA2476406A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
08/28/2003CA2476112A1 Rna interference mediated inhibition of interleukin gene expression using short interfering nucleic acid (sina)
08/28/2003CA2473089A1 Piperidin-4-yl urea derivatives and related compounds as chemokine receptor inhibitors for the treatment of inflammatory diseases
08/28/2003CA2459532A1 Rna interference by modified short interfering nucleic acid
08/28/2003CA2456444A1 Rna interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (sina)
08/28/2003CA2419685A1 Antidiabetic agents
08/27/2003EP1338279A1 Remedies for keratoconjunctival diseases containing farnesyl acetate as the active ingredient
08/27/2003EP1337640A2 NOVEL RETINA-SPECIFIC HUMAN PROTEINS C7orf9, C12orf7, MPP4 AND F379
08/27/2003EP1337560A2 Truncated cd200
08/27/2003EP1337558A2 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor
08/27/2003EP1337527A1 Indolylmaleimide derivatives as protein kinase c inhibitors
08/27/2003EP1337521A1 Salts of an isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
08/27/2003EP1337512A1 (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists
08/27/2003EP1337272A2 Combination of gaba agonists and aldose reductase inhibitors
08/27/2003EP1337271A2 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
08/27/2003EP1337269A2 Association of calpain inhibitors and reactive oxygen species trapping agents
08/27/2003EP1337262A2 Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative
08/27/2003EP1337256A2 Use of thienopyrimidines
08/27/2003EP1337255A2 Use of p38 inhibitors for the treatment of inflammation-enhanced cough
08/27/2003EP1337253A1 Novel compounds
08/27/2003EP1337250A2 Use of p38 inhibitors for the treatment of smoke inhalation
08/27/2003EP1337243A2 Delayed-release pharmaceutical formulations containing proinsulin c-peptide
08/27/2003EP1337218A2 Substituted felbamate derived compounds
08/27/2003EP1140889B1 Compounds and methods for modulation of estrogen receptors
08/27/2003EP0906089B1 Buccal delivery system
08/27/2003EP0891363B1 Heterocyclic compounds and their preparation and use
08/27/2003EP0806206B1 Aqueous compositions containing ciprofloxacine, and related use and process
08/27/2003CN1439009A Imidazo pyrimidine derivatives and triazolopyrimidine derivatives
1 ... 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 ... 531